SAN DIEGO, June 29, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875) and Zhejiang Medicine Co., Ltd. (ZMC) traded on the Shanghai Stock Exchange (600216) today announced the execution of a Joint Venture agreement for the formation of a Joint Venture Company to develop and commercialize MediciNova's MN-221 in China. The completion of the agreement between MNOV and ZMC allows the JV to complete the final approval process with the Ministry of Commerce of the People's Republic of China.
